XtalPi & DoveTree's $6B AI Drug Deal, NASA & Google's Mars Medical Assistant, and More! - Life AI Weekly #29

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in Healthcare and Life Sciences AI. This week, we spotlight significant developments in AI-driven drug discovery and healthcare technology. XtalPi and DoveTree have announced a groundbreaking $6 billion deal to leverage AI in drug discovery, marking a substantial investment in the future of pharmaceuticals. Meanwhile, Stanford AI Lab has identified new drug candidates for COVID-19, showcasing the potential of AI in accelerating medical research.

In healthcare technology, Cognizant has launched an AI Gateway aimed at enhancing healthcare services, and NASA and Google are collaborating on an AI medical assistant designed for Mars missions. These initiatives highlight the diverse applications of AI in improving healthcare delivery and patient outcomes. Stay tuned as we explore these stories and more in this edition.

ARMR Sciences Inc. has announced a capital raise of up to $30 million to develop biodefense solutions against fentanyl and synthetic drug threats.
Healthcare Outcomes Performance Company (HOPCo), based in Phoenix, US, has acquired Amsterdam-based Caro Health, an AI-powered digital health company. This acquisition aims to enhance patient experiences and operational efficiency by integrating Caro's technology into HOPCo's platform.
Biotech startup Tahoe Therapeutics has secured $30 million in funding to develop AI models that simulate living cells, enhancing their research capabilities in predicting cellular reactions.

XtalPi and DoveTree Medicines have announced a $6 billion collaboration to use AI and robotics for drug discovery in fields like oncology, immunology, and neurology. Researchers at Stanford University have identified 92 new COVID-19 drug candidates using AI, with two showing strong potential against resistant strains. On August 11, 2025, Garden launched BLOOM, an AI tool for real-time verification of small-molecule IP landscapes in drug design. Chai Discovery secured $70 million to use AI for designing antibodies, backed by OpenAI and Menlo Ventures. Major pharmaceutical companies, including AstraZeneca, have partnered with Chinese AI drug startups, highlighting China's growing role in drug development.

Yonsei University has introduced the MSI-SEER AI model to predict microsatellite instability and tumor responsiveness, enhancing treatment for gastric and colorectal cancer patients. Emory University researchers have unveiled new physics in dusty plasma dynamics using a machine learning model, challenging existing theories. Meanwhile, Cleveland Clinic and Piramidal have developed an AI model for ICU brain monitoring using EEG data to detect abnormalities more swiftly.

Cognizant launched the TriZetto® AI Gateway to enhance healthcare efficiency and data privacy. NASA and Google are developing an AI medical assistant for Mars missions. Fluent introduced an AI platform for dental credentialing. A study by Caris Life Sciences links AI signatures in breast cancer to improved survival rates. CERTIFY Health and DentalBee partnered to automate dental workflows. Ellipsis Health joined the CMS Health Tech Ecosystem for AI in healthcare. Body Vision Medical received approval in Singapore for its LungVision platform.